---
title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285430037.md"
datetime: "2026-05-06T20:13:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285430037.md)
  - [en](https://longbridge.com/en/news/285430037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285430037.md)
generator: "portal-rs"
---

# REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -2.29.

EBIT: As of FY2026 Q1, the actual value is USD -452.53 M.

#### Operational Metrics

-   **Research and Development Expenses**
    -   For the three months ended March 31, 2026, research and development expenses were $343,970 thousand, an increase from $205,749 thousand for the same period in 2025. This increase was primarily due to higher clinical trial and manufacturing expenses for daraxonrasib and zoldonrasib, increased personnel-related costs, and higher stock-based compensation expense .
-   **General and Administrative Expenses**
    -   General and administrative expenses for the three months ended March 31, 2026, were $101,252 thousand, compared to $35,011 thousand for the three months ended March 31, 2025. The rise was mainly attributed to higher stock-based compensation expense, increased personnel-related costs, commercial preparation activities, and higher administrative costs .
-   **Total Operating Expenses**
    -   Total operating expenses amounted to $445,222 thousand for the three months ended March 31, 2026, up from $240,760 thousand for the same period in 2025 .
-   **Loss from Operations**
    -   The company reported a loss from operations of - $445,222 thousand for the three months ended March 31, 2026, compared to - $240,760 thousand for the three months ended March 31, 2025 .
-   **Net Loss**
    -   Net loss for the three months ended March 31, 2026, was - $453,816 thousand, an increase from - $213,416 thousand for the three months ended March 31, 2025 .

#### Non-Operating Income (Expense), Net

-   **Interest Income**
    -   Interest income was $19,508 thousand for the three months ended March 31, 2026, and $24,915 thousand for the same period in 2025 .
-   **Interest Expense**
    -   Interest expense was - $12,197 thousand for the three months ended March 31, 2026, compared to $0 thousand for the three months ended March 31, 2025 .
-   **Change in Fair Value of Warrant Liability**
    -   The change in fair value of warrant liability was - $15,788 thousand in 2026, compared to $2,439 thousand in 2025 .
-   **Other Expense, Net**
    -   Other expense, net, was - $117 thousand in 2026 and - $10 thousand in 2025 .
-   **Total Non-Operating Income (Loss), Net**
    -   Total non-operating income (loss), net, was - $8,594 thousand for the three months ended March 31, 2026, versus $27,344 thousand for the three months ended March 31, 2025 .

#### Balance Sheet Metrics

-   **Cash, Cash Equivalents and Marketable Securities**
    -   As of March 31, 2026, cash, cash equivalents and marketable securities totaled $1,908,084 thousand, a decrease from $2,025,679 thousand as of December 31, 2025 .
-   **Working Capital**
    -   Working capital was $1,678,314 thousand as of March 31, 2026, down from $1,784,613 thousand as of December 31, 2025 .
-   **Total Assets**
    -   Total assets were $2,253,737 thousand as of March 31, 2026, compared to $2,354,508 thousand as of December 31, 2025 .
-   **Total Liabilities**
    -   Total liabilities increased to $753,820 thousand as of March 31, 2026, from $723,211 thousand as of December 31, 2025 .
-   **Total Stockholders’ Equity**
    -   Total stockholders’ equity was $1,499,917 thousand as of March 31, 2026, a decrease from $1,631,297 thousand as of December 31, 2025 .

#### Other Key Financial Indicators

-   **Stock-Based Compensation Expense**
    -   Stock-based compensation expense was $87.3 million in Q1 2026, significantly higher than $25.1 million in Q1 2025. An additional $44.6 million was recognized in Q1 2026 due to an updated equity compensation program that introduced retirement benefits .
-   **Financings**
    -   In April 2026, Revolution Medicines, Inc. secured $2.2 billion in gross proceeds from concurrent public offerings of common stock and convertible senior notes. The company received $2.1 billion in net proceeds from these financings .

#### Financial Guidance

Revolution Medicines, Inc. updated its full year 2026 GAAP operating expenses guidance to a range of $1.7 billion to $1.8 billion . The company now anticipates full year 2026 stock-based compensation expense to be between $260 million and $280 million . This revised stock-based compensation guidance reflects an approximately $80 million increase from previous estimates, driven by higher projected non-cash stock-based compensation expense .

### Related Stocks

- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [JOYY beats top-line and bottom-line estimates; gives FY 2026 outlook](https://longbridge.com/en/news/296985959.md)
- [Watts Water Technologies (WTS) Runs Near Fair Value, Is The Stock Now Too Pricey?](https://longbridge.com/en/news/297071015.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)
- [Ameriprise Financial declares Q3 2026 dividend of R$ 1.48 per unit](https://longbridge.com/en/news/297021432.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**